Gokul M Das

8PUBLICATIONS
27CO-AUTHORS
Cancer geneticsCancer cell biologyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 28, 2026
Correction: Oturkar et al. Estrogen Receptor-Beta2 (ERβ2)-Mutant p53-FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC). Cancers 2022, 14, 1120.

|Jul 17, 2025
Integrative spatial omics reveals distinct tumor-promoting multicellular niches and immunosuppressive mechanisms in Black American and White American patients with TNBC.

Qian Zhu, Akhila Balasubramanian, Jaya Ruth Asirvatham

|Feb 01, 2025
Interaction between Estrogen Receptors and p53: A Broader Role for Tamoxifen?

Gokul M Das, Chetan C Oturkar, Vishnu Menon

|Mar 08, 2023
Immature natural killer cells promote progression of triple-negative breast cancer.

Gatha Thacker, Samantha Henry, Ajeya Nandi

|Feb 11, 2023
Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53.

Lauren Scarpetti, Chetan C Oturkar, Dejan Juric

|Mar 10, 2022
Estrogen Receptor-Beta2 (ERβ2)-Mutant p53-FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC).

Chetan C Oturkar, Nishant Gandhi, Pramod Rao

Pageof 2

Frequent Collaborators

2 joint publications

Chetan C Oturkar

2 joint publications

Kevin H Eng

2 joint publications

Austin Miller

2 joint publications

Emese Zsiros